A Study to Assess the Adverse Events and Effectiveness of Rapid Acoustic Pulse (RAP) Device in Adult Participants for the Appearance of Cellulite

Phase 4

Completed

Conditions: Cellulite

Interventions: Device: Rapid Acoustic Pulse

Registration Number: NCT05730335

Lead Sponsor: Zeltiq Aesthetics

Brief Summary: Cellulite is the rippling or dimpling of the skin most commonly located on the thighs and buttocks of women. Its appearance and texture are often likened to that of "cottage cheese" or an orange peel. Rapid Acoustic Pulse (RAP) is an electrohydraulic (EH) device developed to improve the appearance of cellulite through microscopic disruption of the connection between the skin and underlying tissue leading to a reduction in the severity of dimples and ridges. The purpose of this study is to assess adverse events and effectiveness of RAP in adults seeking treatment of cellulite.

RAP is an FDA approved device for the long-term improvement in the appearance of cellulite in the buttocks and thighs. Participants 18-50 years of age seeking treatment of cellulite will be enrolled. Up to 60 participants will be enrolled in the study at 4 sites in the United States.

Participants will receive 2 separate cellulite treatment sessions. Each treatment session will consist of RAP treatment delivered to bilateral thigh and/or buttock areas using the same treatment settings for both sides. The study duration is up to 60 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 59

Inclusion Criteria

Participants seeking treatment of cellulite in the thigh and/or buttock areas.
Areas of moderate to severe cellulite on bilateral thigh and/or buttock using the Cellulite Dimple - At Rest Scale at Baseline with grades of 2 or 3 based on review of photos taken under the same lightening conditions planned for the trial.
Participant will not have had invasive or energy-based cellulite (liposuction, subcision, RF, laser, ESWT, cryo-lipolysis, muscle stimulation, etc.) treatments in the treatment areas in the prior 12 months.
Participant will not have used topical based cellulite treatments for prior 3 months and will not use during the trial
Participant will not have used spray-on tanning treatments for 3 months prior to or during the term of the trial.

Exclusion Criteria

Metal or plastic implants (vascular stent, or implants in the hips, knees, etc.) in the treatment areas.
Active electronic implants such as pacemakers, defibrillators
History of coagulopathy and/or on anticoagulant medication
Skin disorders (skin infections or rashes, psoriasis, etc.) in the treatment areas.
Medical disorder that would hinder wound healing or immune response.
Any surgical procedure in the treatment areas in the prior 3 months or planned during the duration of the study.
Any other condition/disease/situation which, as deemed by the PI, would preclude participant from safely participating in or completing the study visits or that may confound study results.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Rapid Acoustic Pulse (RAP)	Rapid Acoustic Pulse	Participants will receive 2 separate RAP cellulite treatments sessions.

Primary Outcome Measures

Name	Time	Method
Percentage of Before and After Side-by-side Photographs Correctly Identified by At Least 2 of 3 Blinded Reviewers From the Independent Physician Reviewer (IPR) Panel	Baseline, Week 12	Photographs of the treatment areas were taken at baseline, and at 12-weeks after the first treatment to determine if the RAP treatment had the effect of improvement in the appearance of cellulite. The photographs were assessed by blinded independent reviewers (IPR) to correctly identify the 12-weeks post-treatment photographs from randomly placed side-by-side comparison of before and after photographs. Reported here is the percentage (%) of images that were correctly identified by at least 2 out of 3 blinded independent reviewers.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With "Agree" or "Strongly Agree" Responses to the Participant Satisfaction Survey in the Improvement in Appearance of Cellulite	Baseline, Week 12	The study participant responded to the Participant Satisfaction Survey statement, "In comparison to the pre-treatment photo, the 12 week photograph of the treatment area appears improved." Response choices to this statement were "Strongly Agree", "Agree", "Neutral", "Disagree", and "Strongly Disagree", with "Strongly Agree" representing the greatest perceived improvement in the appearance of cellulite. Reported here is the number of participants who responded with "Agree" or "Strongly Agree". Data are reported split per response to photographs on the left and right side of the body.
Number of Participants With Device-related or Treatment-related: Adverse Events (AEs), Serious AEs (SAEs), Adverse Device Events (ADEs), Serious ADEs (SADEs), Unanticipated AEs or Unanticipated ADEs	Week 1 up to Week 12	An AE was defined as any unfavorable or unintended sign, symptom, or disease that occurred or was reported by the participant to have occurred, or a worsening of a pre-existing condition. A SAE resulted in death, was life threatening, required hospitalization, was a persistent or significant disability/incapacity, a birth defect, or was an event that required medical intervention. An ADE was defined as any AE with a reasonable possibility (definitely, probably, possibly, or remotely related) that the event may have been caused by the study device only.

Trial Locations

Locations (4): Bellaire Dermatology
🇺🇸
Bellaire, Texas, United States
Chicago Cosmetic Surgery and Dermatology
🇺🇸
Chicago, Illinois, United States
Skin and Laser Surgery Center of New England
🇺🇸
Nashua, New Hampshire, United States
Union Derm
🇺🇸
New York, New York, United States